Latest Regulatory News

Page 533 of 906
Dusk Group Limited reported solid financial growth for FY25, with revenue up 7.8% and net profit rising 5.5%, underpinned by strong online sales and strategic store expansions.
Logan Eniac
Logan Eniac
29 Aug 2025
Novatti Group reports a record $51.8 million revenue for FY25 alongside a 65% improvement in underlying EBITDA, signaling a successful turnaround and a strategic pivot back to growth.
Claire Turing
Claire Turing
29 Aug 2025
PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.
Ada Torres
Ada Torres
29 Aug 2025
Virgin Australia has reported a robust FY25 performance, surpassing IPO forecasts with strong earnings growth and operational improvements. The airline reaffirms its positive outlook for FY26, underpinned by fleet expansion and ongoing transformation benefits.
Victor Sage
Victor Sage
29 Aug 2025
Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.
Ada Torres
Ada Torres
29 Aug 2025
PainChek Limited reported a 24% revenue increase to $4.8 million for FY25, narrowing its net loss by 7%, while progressing toward FDA clearance for its Adult PainChek App in the US and launching its Infant App in Australia.
Victor Sage
Victor Sage
29 Aug 2025
Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.
Ada Torres
Ada Torres
29 Aug 2025
Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.
Ada Torres
Ada Torres
29 Aug 2025
NobleOak Life Limited reported robust FY25 results, with a 20% increase in in-force premiums and a 22% rise in underlying NPAT, underpinned by strategic investments in AI and a transition to a capital-efficient Life Company structure.
Claire Turing
Claire Turing
29 Aug 2025
NobleOak Life Limited reported a robust 20% growth in in-force premiums and a 22% rise in underlying profit for FY25, surpassing guidance and setting a clear path to $1 billion in-force premium. Strategic partnerships, acquisitions, and product innovation underpin its strong outlook for FY26.
Victor Sage
Victor Sage
29 Aug 2025
NobleOak Life Limited reported a robust 22% increase in underlying net profit after tax for FY25, driven by strong premium growth and expanding market share. Despite a statutory profit dip due to one-off costs, the insurer plans to reinvest cash flows to fuel future growth and transition to a Life Company structure.
Victor Sage
Victor Sage
29 Aug 2025
PEXA Group delivered a solid FY25 with 16% revenue growth and a 21% rise in EBITDA, while preparing for a UK platform launch backed by NatWest. Despite statutory losses from impairments, the company strengthened its balance sheet and outlined a confident FY26 outlook.
Sophie Babbage
Sophie Babbage
29 Aug 2025